Gene Therapy Market

Gene Therapy Market Research, 2030

The global Gene Therapy Market Size was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030, growing at a CAGR of 22.8% from 2021 to 2030. Gene is a functional hereditary unit of life that carries a set of instructions for a particular function. Gene therapy is the advanced treatment applied for cancer, chronic disease, infectious disease, and blood disorders. Gene therapy involves the partial or full replacement of defective genes in a patient's body with healthy ones to treat or prevent disease proliferation. There are two types of gene therapy based on the location of the target gene on a chromosome including somatic gene therapy & germline gene therapy. It can be applied for the treatment of several diseases, such as Parkinson’s, hemophilia, cystic fibrosis, Alzheimer’s, brain tumors, cancer, AIDS, SCID, and others. The transgene is transferred into the host cell by biological vectors, such as the virus, liposome, and plasmids. These vectors are further categorized as viral vectors & non-viral vectors. The viral vector consists of retrovirus, lentivirus, adenovirus, and adeno-associated vector. The non-viral vector includes liposomes, transposons, and plasmids. The physical methods are also available for gene transfer, such as electroporation, sonication, gene gun, and photoporation

The overall impact of COVID-19 remains negative on the gene therapy market, owing to a decline in the number of cancer patient visits to hospitals & clinics for gene therapy (ICI), which lead to a decline in demand for gene therapy products. For instance, according to the NCBI in 2020, around a 50% patient decrease is reported for cancer care in the U.S., and overall cancer therapies are declined by 50% during COVID-19 which leads to a decline in demand for gene therapy products in the market.

The key factor that drives the Gene Therapy Market Growth is an increase in the prevalence of chronic disorders such as cancer, rare disease genetic disorders, and others globally. In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and a rise in the prevalence of cancer fuel the growth of the market. Furthermore, an increase in healthcare expenditure, the presence of advanced healthcare infrastructure, availability of reimbursements provide Gene Therapy Market Opportunity. However, the high cost of gene therapies is expected to hamper the market growth to a certain extent during the forecast period.

The gene therapy market is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia viruses, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.

By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By Vector Type Segment Review

By vector type, the gene therapy market is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia viruses, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others.

The non-viral vector segment holds the largest Gene Therapy Market Size and is estimated to witness the highest CAGR during the forecast period. Owing to the rise in the incidence of cancer and other target diseases, the availability of reimbursements policies, and the increase in funding for gene therapy research are the key factors anticipating the growth of the market in upcoming years.

By Therapy Type Segment Review

By therapy type, the market is classified into ex vivo therapy and in vivo therapy. The in vivo therapy segment held the largest market share in 2020. An increase in the adoption of in vivo gene therapies globally is expected to drive the growth of the market in the future

By Gene Type Segment Review

By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. The antigen segment held the largest market share in 2020. An increase in the prevalence of autoimmune diseases, cancer, and R&D in antigen-based gene therapies are key factors anticipated to drive the growth of the market in upcoming years.

By Application Segment Review

By application, the Gene Therapy Industry is categorized into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and other diseases. The oncological disorders segment has highest Gene Therapy Market Share. The availability of many gene therapy products that can be used to treat cancer and a large patient population base is expected to drive the growth of the market in upcoming years.

Region Segment Review

By region, the Gene Therapy Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest Gene Therapy Market Share in 2020. Owing to the rise in prevalence of chronic diseases, high and growing healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of major market players, the gene therapy market in North America is expected to grow during the forecast period.

The key players operating in the global Gene Therapy Industry include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Unique N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.

The gene therapy market is segmented into Vector Type, Therapy, Gene Type and Application.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene therapy market analysis from 2020 to 2030 to identify the prevailing gene therapy market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the gene therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global gene therapy market trends, key players, market segments, application areas, and market growth strategies.

 Gene Therapy Market Report Highlights